Head to head
GLP-1 against Semaglutide
The hormone and the analogue. Native GLP-1 is broken down within minutes, which is the entire reason the drug class exists, so comparing them is really a question about half-life rather than about effect.
Column A
GLP-1Glucagon-Like Peptide-1 (native incretin hormone)
The natural gut hormone behind the entire GLP-1 drug class, released after eating to boost insulin and reduce appetite.
Column B
SemaglutideSemaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Side by side, on the facts we can check
| Attribute | GLP-1 | Semaglutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | The hormone itself is not a medicine and is not sold as one. The drugs built from it are approved: semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide, dulaglutide, exenatide and tirzepatide all act at this receptor and are FDA-approved prescription medicines. | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) |
| Half-life | ~1-2 minutes (native) | ~7 days |
| Molecular weight | 3,297.7 Da | 4,113.6 Da |
| Mechanism | Activates GLP-1 receptors to drive glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce food intake. | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. |
| Human studies cited | 2 | 5 |
| Legal status, US | Not a medicine; endogenous signalling molecule | FDA-approved, prescription only |
Frequently asked questions
What is the difference between GLP-1 and Semaglutide?
GLP-1: The natural gut hormone behind the entire GLP-1 drug class, released after eating to boost insulin and reduce appetite. Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Which has stronger research evidence, GLP-1 or Semaglutide?
This database does not grade compounds. It counts what was run in people: 2 of the 5 studies cited on the GLP-1 profile were human work, against 5 of 5 for Semaglutide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are GLP-1 and Semaglutide FDA-approved?
GLP-1: The hormone itself is not a medicine and is not sold as one. The drugs built from it are approved: semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide, dulaglutide, exenatide and tirzepatide all act at this receptor and are FDA-approved prescription medicines.. Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management).
Related posts
Blog articles that cover GLP-1 or Semaglutide, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.